Navigation Links
Cumberland Pharmaceuticals Announces Appointments
Date:12/18/2007

NASHVILLE, Tenn., Dec. 18 /PRNewswire/ -- Cumberland Pharmaceuticals is pleased to announce the appointment of two senior executives.

David L. Lowrance has been promoted to Vice President and Chief Financial Officer. In this role, he is responsible for overseeing the company's accounting and financial activities, including financial reporting and planning. Mr. Lowrance has 17 years of financial and accounting experience, joining Cumberland in 2003 as Director of Finance and Accounting. He spent eight years with two global conglomerates, including four years as senior vice president for Icore International. Prior to this, Mr. Lowrance spent four years at Ernst & Young, LLP. A graduate of the University of Georgia, he is a certified public accountant.

Doug Jack has joined the company as Senior Manager of SEC Reporting. He is responsible for the preparation of all SEC-required financial reports. Mr. Jack brings more than 14 years of accounting and financial experience to his position. Prior to joining Cumberland, he spent eight years as audit manager with Ernst & Young and PricewaterhouseCoopers, and served as CFO and controller at Southern Specialty Brands. A certified public accountant, he is a graduate of the University of Georgia.

"We are fortunate to work with these outstanding individuals who bring great depth of experience and knowledge in their respective areas," said A.J. Kazimi, Cumberland's Chief Executive Officer. "Each will play an important role in taking the company to the next level as we continue to grow and capitalize on opportunities created by the shifting pharmaceutical landscape."

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription strength laxative. The Company is also developing Amelior(R) which is in Phase III studies for the treatment of both pain and fever. Cumberland is dedicated to providing innovative products which improve quality of care for patients.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... ... , ... Mystic Buddha Publishing House presents Valentine’s Day tips on different forms ... - Dr. Frederick Lenz. , According to Publisher Roger Cantu, “Blue Skies ... teaching and helping others. Valentine’s Day celebrates love in all its forms, and ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to ... students from U.S. universities who will draw from Siemens’ deep knowledge of ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the ... , As Winston Churchill said, “Those who don’t learn from history are ... what to expect when they come knocking this year. But that takes time. , ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016 The primary goal of ... adoption patterns on the usage of liquid biopsy. Key ... - Timeframe of liquid biopsy adoption amidst ... and Evs—by organization type - Sample inflow to conduct ... saliva, stool, serum, and so on. - Correlation analysis ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Walgreens has ... across 39 states and Washington, D.C. ... a move that was commended by shareholder advocacy organization As ... at As You Sow. "Many people hold on to unneeded ... which can have tragic consequences." --> Conrad ...
(Date:2/11/2016)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... other birth tissues, human skin and bone, and patent-protected ... products and therapies, announced today that it will present ... in New York , NY.  Parker ... Senken , Chief Financial Officer and Chris Cashman ...
Breaking Medicine Technology: